Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Asfar

Showing results (1-10 of 200) with videos related to

Pageof 20
Sort By:
Intensive Care Medicine|April 4, 2003
Terlipressin in chronic hyperdynamic endotoxic shock: is it safe?Pierre Asfar
American Journal of Respiratory and Critical Care Medicine|June 2, 2015
Update in sepsis and acute kidney injury 2014Frédérique Schortgen, Pierre Asfar
American Journal of Respiratory and Critical Care Medicine|April 21, 2022
A Rationale for the Use of Norepinephrine after the Control of Bleeding in Hemorrhagic Shock?Pierre Asfar, Clive May
Critical Care Medicine|June 17, 2015
Drug-Induced "Suspended Animation": Can a Dream Become True?Pierre Asfar, Peter Radermacher
Critical Care (London, England)|August 12, 2009
Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?Pierre Asfar, Peter Radermacher
The Lancet. Respiratory Medicine|May 3, 2017
Is hyperoxaemia a risk factor for ICU-acquired pneumonia? - Authors' replyPierre Asfar, Frédérique Shortgen, Peter Radermacher
Intensive Care Medicine|July 14, 2018
MAP of 65: target of the past?Pierre Asfar, Peter Radermacher, Marlies Ostermann
Critical Care (London, England)|July 17, 2014
Is pharmacological, H₂S-induced 'suspended animation' feasible in the ICU?Pierre Asfar, Enrico Calzia, Peter Radermacher
Shock (Augusta, Ga.)|February 18, 2016
Norepinephrine, the Intensivist's Swiss Army Knife for Circulatory Shock?Pierre Asfar, Christoph Thiemermann, Peter Radermacher
Best Practice & Research. Clinical Anaesthesiology|August 8, 2008
Impact of vasopressin analogues on the gut mucosal microcirculationPierre Asfar, Hendrik Bracht, Peter Radermacher
Pageof 20

Showing results (1-10 of 200) with videos related to

Sort By:
Pageof 20
Intensive Care Medicine|April 4, 2003
Terlipressin in chronic hyperdynamic endotoxic shock: is it safe?Pierre Asfar
American Journal of Respiratory and Critical Care Medicine|June 2, 2015
Update in sepsis and acute kidney injury 2014Frédérique Schortgen, Pierre Asfar
American Journal of Respiratory and Critical Care Medicine|April 21, 2022
A Rationale for the Use of Norepinephrine after the Control of Bleeding in Hemorrhagic Shock?Pierre Asfar, Clive May
Critical Care Medicine|June 17, 2015
Drug-Induced "Suspended Animation": Can a Dream Become True?Pierre Asfar, Peter Radermacher
Critical Care (London, England)|August 12, 2009
Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?Pierre Asfar, Peter Radermacher
The Lancet. Respiratory Medicine|May 3, 2017
Is hyperoxaemia a risk factor for ICU-acquired pneumonia? - Authors' replyPierre Asfar, Frédérique Shortgen, Peter Radermacher
Intensive Care Medicine|July 14, 2018
MAP of 65: target of the past?Pierre Asfar, Peter Radermacher, Marlies Ostermann
Critical Care (London, England)|July 17, 2014
Is pharmacological, H₂S-induced 'suspended animation' feasible in the ICU?Pierre Asfar, Enrico Calzia, Peter Radermacher
Shock (Augusta, Ga.)|February 18, 2016
Norepinephrine, the Intensivist's Swiss Army Knife for Circulatory Shock?Pierre Asfar, Christoph Thiemermann, Peter Radermacher
Best Practice & Research. Clinical Anaesthesiology|August 8, 2008
Impact of vasopressin analogues on the gut mucosal microcirculationPierre Asfar, Hendrik Bracht, Peter Radermacher
Pageof 20